Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Roots Analysis

FEBRUARY 14, 2023

Presently, outsourcing of liposomes development and manufacturing related services has become a popular practice. Drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise.

Development 52

Development Manufacturing Drug Delivery Systems Contract Manufacturing 52

Roots Analysis

MARCH 21, 2022

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Marketing 52

Delveinsight

MARCH 2, 2021

Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine therapies for patients with chronic kidney diseases (CKD). The duo plans to jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines. HitGen & UPPTHERA Collaborate for Drug Delivery Research.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

pharmaphorum

SEPTEMBER 22, 2021

Texas-based Abexxa has been on the Boehringer’s radar since it was set up, as it provided seed funding for the preclinical-stage company in 2016, buying into its approach of developing antibodies against targets inside cancer cells, rather than on the cell membrane. Last December, Boehringer paid €1.8

Antibody 92

Antibody Drug Delivery Vaccination Vaccine 92

Roots Analysis

FEBRUARY 26, 2024

However, certain biological targets have long eluded drug development efforts. Advances in drug discovery and development technologies / platforms have increased the likelihood of targeting a number of the aforementioned types of biological targets.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Drug Delivery Development 52

pharmaphorum

APRIL 29, 2021

It will enable them understand the biology of the BBB, explore the latest technological innovations and develop more predictive preclinical models. The Blood-Brain Barrier Summit is the industry’s first meeting dedicated to targeting the blood-brain barrier in order to develop clinically efficacious therapeutics for CNS indications.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

Roots Analysis

MARCH 16, 2022

In order to promote the use of exosomes in various therapeutic applications including targeted drug delivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Want additional details on the pipeline?

Marketing 59

Marketing Manufacturing Drug Delivery Drug Delivery Systems 59

Drug Discovery World

JUNE 22, 2023

This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies. “We The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

pharmaphorum

MARCH 15, 2022

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. Sanofi has partnered with drug delivery specialist Enable Injections to develop the subcutaneous formulation.

Trials 97

Trials Sales Drug Delivery Antibody 97

Roots Analysis

OCTOBER 13, 2023

Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drug delivery strategies to enhance the potent delivery of the drug to the site of action.

Drugs 40

Drugs Antibody RNA Genetics 40

Roots Analysis

AUGUST 8, 2023

Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drug delivery have been highlighted in the figure.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs In-Vivo 52

pharmaphorum

JUNE 22, 2021

GlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop a new generation of long-acting HIV drugs, as it prepares to give a much-anticipated update to shareholders tomorrow. So far, all the other antibodies are also delivered by intravenous infusion.

Antibody 52

Antibody Protein Drug Delivery FDA Approval 52

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

pharmaphorum

OCTOBER 11, 2022

The results were disappointing, with only a minority of patients getting the intranasal regimen showing signs of SARS-CoV-2 antigen-specific antibody responses in the mucosa, which according to the researchers “rarely” exceeded the levels one would see after a COVID-19 infection.

Vaccination 116

Vaccination Vaccine Immune Response Development 116

The Pharma Data

MARCH 15, 2022

Investment will accelerate the overall Sarclisa ® development program Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa ® (isatuximab). For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 16, 2021

It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. JS Bio’s parent company. Making this partnership is a mutually beneficial cooperation.”.

Protein 52

Protein Production Antibody In-Vitro 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. Earlier in his career, he ran business-development functions at Amgen and Baxter. and TAIPEI, Taiwan, Oct.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

The Pharma Data

APRIL 8, 2021

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D, said: “Our data at AACR reflect a robust early-stage pipeline, poised to deliver life-changing medicines to patients living with cancer. Data identifying a novel immunosuppressive myeloid gene signature for clinical biomarker development.

DNA 52

DNA Medicine Genome Genomics 52

Delveinsight

JANUARY 22, 2021

Similar is the picture of the Thrombocytopenia Drugs Market. Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved shortly. Major key players involved in developing novel Thrombocytopenia treatment drugs market include UCB Biopharma , Principia Biopharma , Baxalta/Takeda , Argenx , etc.

Marketing 65

Marketing Drugs Antibody Compliance 65

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

The Pharma Data

JANUARY 17, 2021

Prior to this, he spent nine years at Gilead Sciences, where most recently he was Chief Scientific Officer and Head of Research & Development. At Gilead he led the organization in the successful filing of numerous New Drug Applications (NDAs) and supplemental label updates across multiple therapeutic areas.

Life Science 40

Life Science Drug Delivery Engineer Drugs 40

pharmaphorum

DECEMBER 18, 2020

With the aim of achieving a higher quality of life for those with unfavourable prognoses, this project, funded by Innovate UK, the UK’s innovation agency, brings together partners with a wealth of experience and specialist know-how in the areas of nanoparticle development, drug delivery and bioimaging.

Drug Delivery 52

Drug Delivery Medicine Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 17, 2021

It was developed with Genmab. The two companies entered a global development, manufacture and commercialization deal in August 2021. Darzalex Faspro is the only CD38-directed antibody that has been approved for subcutaneous injection for multiple myeloma, and now AL amyloidosis. Most Read Today. Source link.

FDA Approval 52

FDA Approval Drug Delivery Doctors Doctor 52

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Concluding Remarks.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

pharmaphorum

DECEMBER 15, 2022

Oxsonics Therapeutics, which offers an ultrasound-based drug delivery platform, appointed Jérôme Marzinski, a board member at Cimon Medical and former CEO of ophthalmic diagnostic company Visiometrics into its top job. More CEO shakeups. Bungay formerly served as CEO of Chroma Therapeutics and COO of Mereo Biopharma.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

XTalks

OCTOBER 27, 2021

Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.

Drug Delivery Systems 104

Drug Delivery Systems Drug Delivery FDA Approval Drugs 104

The Pharma Data

MAY 15, 2023

Roche’s Chief Medical Officer and Head of Global Product Development. “If If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 7 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

JANUARY 24, 2021

However, VEGF is not the only pathway involved in the development and progression of this complex condition. Faricimab is the first bispecific antibody designed for the eye. chief medical officer and head of Global Product Development. chief medical officer and head of Global Product Development. “We About faricimab.

Antibody 40

Antibody Medicine Drug Delivery Development 40

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. Chief Medical Officer and Head of Global Product Development. “We

Antibody 40

Antibody In-Vitro Development Trials 40

XTalks

AUGUST 30, 2022

CNS drugs treat a range of neurologic and psychiatric disorders, such as psychosis, depression, Parkinson’s disease, multiple sclerosis and epilepsy. Direct CNS administration techniques facilitate drug delivery to the brain to treat neurological disorders and these approaches are vital for CNS targets. Intrathecal Chemotherapy.

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

SEPTEMBER 13, 2023

Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Development 40

Development Antibody Protein Drug Delivery Systems 40

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

JUNE 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. “If Roche has a robust phase III clinical development programme underway for PDS, including the Portal, Pagoda and Pavilion studies. 11,12 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. Over the years, a range of different CPPs have been developed, including natural translocating proteins through to newly-designed computer-prediction sequences 3.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

AUGUST 31, 2021

Vice President, Late Development and Global Medical Affairs, Janssen Research & Development, LLC. “We TAR-200 is an investigational drug delivery system, enabling controlled release of gemcitabine into the bladder, increasing dwell time and local drug exposure. For more information, visit www.ERLEADA.com.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Trials Drugs 52